@article{HaeusnerHerbstBittorfetal.2021,
  author    = {Haeusner, Sebastian and Herbst, Laura and Bittorf, Patrick and Schwarz, Thomas and Henze, Chris and Mauermann, Marc and Ochs, Jelena and Schmitt, Robert and Blache, Ulrich and Wixmerten, Anke and Miot, Sylvie and Martin, Ivan and Pullig, Oliver},
  title     = {From Single Batch to Mass Production-Automated Platform Design Concept for a Phase II Clinical Trial Tissue Engineered Cartilage Product},
  series = {Frontiers in Medicine},
  volume    = {8},
  journal   = {Frontiers in Medicine},
  issn      = {2296-858X},
  doi       = {10.3389/fmed.2021.712917},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-244631},
  year      = {2021},
  abstract  = {Advanced Therapy Medicinal Products (ATMP) provide promising treatment options particularly for unmet clinical needs, such as progressive and chronic diseases where currently no satisfying treatment exists. Especially from the ATMP subclass of Tissue Engineered Products (TEPs), only a few have yet been translated from an academic setting to clinic and beyond. A reason for low numbers of TEPs in current clinical trials and one main key hurdle for TEPs is the cost and labor-intensive manufacturing process. Manual production steps require experienced personnel, are challenging to standardize and to scale up. Automated manufacturing has the potential to overcome these challenges, toward an increasing cost-effectiveness. One major obstacle for automation is the control and risk prevention of cross contaminations, especially when handling parallel production lines of different patient material. These critical steps necessitate validated effective and efficient cleaning procedures in an automated system. In this perspective, possible technologies, concepts and solutions to existing ATMP manufacturing hurdles are discussed on the example of a late clinical phase II trial TEP. In compliance to Good Manufacturing Practice (GMP) guidelines, we propose a dual arm robot based isolator approach. Our novel concept enables complete process automation for adherent cell culture, and the translation of all manual process steps with standard laboratory equipment. Moreover, we discuss novel solutions for automated cleaning, without the need for human intervention. Consequently, our automation concept offers the unique chance to scale up production while becoming more cost-effective, which will ultimately increase TEP availability to a broader number of patients.},
  language  = {en}
}
@article{SchwabBussPulligetal.2021,
  author    = {Schwab, Andrea and Buss, Alexa and Pullig, Oliver and Ehlicke, Franziska},
  title     = {Ex vivo osteochondral test system with control over cartilage defect depth - A pilot study to investigate the effect of oxygen tension and chondrocyte based treatments in chondral and full thickness defects in an organ model},
  series = {Osteoarthritis and Cartilage Open},
  volume    = {3},
  journal   = {Osteoarthritis and Cartilage Open},
  number    = {2},
  doi       = {10.1016/j.ocarto.2021.100173},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-260511},
  year      = {2021},
  abstract  = {Objective Cartilage defect treatment strategies are dependent on the lesion size and severity. Osteochondral explant models are a platform to test cartilage repair strategies ex vivo. Current models lack in mimicking the variety of clinically relevant defect scenarios. In this controlled laboratory study, an automated device (artificial tissue cutter, ARTcut®) was implemented to reproducibly create cartilage defects with controlled depth. In a pilot study, the effect of cartilage defect depth and oxygen tension on cartilage repair was investigated. Design Osteochondral explants were isolated from porcine condyles. 4 ​mm chondral and full thickness defects were treated with either porcine chondrocytes (CHON) or co-culture of 20\% CHON and 80\% MSCs (MIX) embedded in collagen hydrogel. Explants were cultured with tissue specific media (without TGF-β) under normoxia (20\% O\(_2\)) and physiological hypoxia (2\% O\(_2\)). After 28 days, immune-histological stainings (collagen II and X, aggrecan) were scored (modified Bern score, 3 independent scorer) to quantitatively compare treatment outcome. Results ARTcut® represents a software-controlled device for creation of uniform cartilage defects. Comparing the scoring results of the MIX and the CHON treatment, a positive relation between oxygen tension and defect depth was observed. Low oxygen tension stimulated cartilaginous matrix deposition in MIX group in chondral defects and CHON treatment in full thickness defects. Conclusion ARTcut® has proved a powerful tool to create cartilage defects and thus opens a wide range of novel applications of the osteochondral model, including the relation between oxygen tension and defect depth on cartilage repair.},
  language  = {en}
}